All In MedTech

Device Trial Radar · NCT00830440

A Multicenter Study for Pre-Surgical Weight Loss

A Multi-Center, Pilot Efficacy Study of the GI Sleeve™ for Pre-Surgical Weight Loss

Last checked: Nov 20, 2026Latest source record: May 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

43

Actual

Start

Jan 2007

Primary completion

Mar 2008

Study completion Sep 2008

Sponsor

Lead sponsor
Morphic Medical Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jan 28, 2009

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and initial efficacy of the EndoBarrier device compared to a diet control in patients who require weight loss prior to their Bariatric surgery. It is a randomized, prospective controlled, open label, pilot study of 40 patients. Thiry patients will receive an implant of the EndoBarrier device and the other 10 patients will receive the principle investigator's standard of care diet program. All patients will be treated for 12 weeks with the exception of the last 10 device patients who will continue to 24 weeks if the principle investigator determines that it is safe and in their best interest to continue. The primary efficacy endpoint is: * Assessment of the difference in % excess weight loss between the 2 groups Secondary endpoints are: * Resolution or Improvement in type II Diabetic status as defined as: * Resolution = patient is off their diabetes medication and has normal diabetic blood parameters (fasting glucose) * Improvement = normalizing diabetic blood parameters (fasting glucose) and/or a reduction in dosing or frequency of their diabetic medication * The percent of patients who achieve at least a 10% excess weight loss will be calculated as a secondary outcome.

Conditions

  • Obesity

Interventions

  • EndoBarrier DeviceDevice

    NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks

  • Diet & Lifestyle CounselingBehavioral

    NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Weight Change From Baseline at 12 Weeks in kgTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital Maastricht

    Maastricht, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.